Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study

Alfredo Berruti*, Rossella Libe, Marta Lagana, Hester Ettaieb, Mohamad Anas Sukkari, Jerome Bertherat, Richard A. Feelders, Salvatore Grisanti, Jerome Cartry, Gherardo Mazziotti, Sandra Sigala, Eric Baudin, Harm Haak, Mouhammed Amir Habra, Massimo Terzolo

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)311-320
Number of pages10
JournalEuropean Journal of Endocrinology
Volume180
Issue number5
DOIs
Publication statusPublished - May 2019

Keywords

  • CLINICAL-PRACTICE GUIDELINES
  • PROSTATE-CANCER PATIENTS
  • ZOLEDRONIC ACID
  • TARGETED THERAPIES
  • EUROPEAN NETWORK
  • BREAST-CANCER
  • LUNG-CANCER
  • PHASE-III
  • MANAGEMENT
  • HYPERCORTISOLISM

Cite this

Berruti, A., Libe, R., Lagana, M., Ettaieb, H., Sukkari, M. A., Bertherat, J., Feelders, R. A., Grisanti, S., Cartry, J., Mazziotti, G., Sigala, S., Baudin, E., Haak, H., Habra, M. A., & Terzolo, M. (2019). Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. European Journal of Endocrinology, 180(5), 311-320. https://doi.org/10.1530/EJE-19-0026